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sels or the inferior mesenteric artery (IMA); type III,
caused by fabric tears, migration, or disintegration of one
of the stent-graft components; or type IV, caused by graft
wall porosity. The purpose of this study was to report our
initial experience in the endovascular treatment of patients
with type II endoleaks by superselective catheterization
and subsequent embolization of the feeding arteries. We
present the technical details of the procedures, the imme-
diate procedural results, and early follow-up results.
MATERIAL AND METHODS
Between March 1996 and November 1999, 60
patients with infrarenal abdominal aortic aneurysms
(AAAs) were treated with stent-graft implantation. In 53
patients, a Vangard prosthesis (Boston Scientific, La
Garenne Colombes, France) was implanted, and in the
remaining seven patients, a Talent prosthesis (Medtronic,
Boulogne-Billancourt, France) was implanted. In this
period, results of magnetic resonance imaging (MRI), heli-
cal computed tomography (CT), or both were positive for
endoleak in 27 of 60 patients (45%). An angiography was
performed only when the aneurysm maximum diameter
expanded or when the endoleak was confirmed by means
of helical CT or MRI after a 6-month interval (Fig 1).
Diagnostic arteriography. Arteriography was per-
formed according to a standardized protocol with a 5F
pigtail catheter inserted through a transfemoral or trans-
brachial approach, with the Seldinger technique. A bolus
of molsidomine (1 mg), a nitrate-like vasodilator, was
Bifurcated covered stent-grafts are a promising advance
in the treatment of infrarenal aortic aneurysms.1-3 This
new procedure has emerged as a possible alternative to
surgery in patients selected by means of preoperative
imaging. In addition, endovascular techniques could be
used in patients who are at a high risk for surgery.4
However, despite a high rate of immediate procedural suc-
cess, enthusiasm for the widespread adoption of endovas-
cular techniques has been tempered by the persistent risk
of rupture because of the high rate of endoleaks encoun-
tered during follow-up.5-7
Endoleaks have been reported in as many as 40% of
patients after initially successful procedures. This classifica-
tion of endoleaks has been proposed8,9: type I, caused by
mechanical separation of the components of the prosthe-
sis from the native vasculature; type II, caused by persis-
tent perfusion of the aneurysm sac through feeding
arteries that generally originates from the iliolumbar ves-
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Purpose: We report the procedural details and immediate results of treatment of type II endoleaks after aortic stent-graft
implantation.
Methods: In a consecutive series of patients who had either Vangard (n = 53) or Talent (n = 7) aortic stent-grafts
implanted, type II endoleaks were confirmed by means of angiography in 18 patients, with a mean (± SD) age of 69 ±
11 years; 16 patients had Vangard stent-grafts, and two patients had Talent stent-grafts. After superselective catheter-
ization of the feeding vessel, with 3F microcatheters, and liberal injections of vasodilators, embolization was performed
with either a mixture of biologic glue and Lipiodol (n = 16) or Microcoils (n = 2).
Results: The procedure was performed through the femoral artery in 16 patients and through the brachial artery in the
remaining two patients. Overall, superselective catheterization and embolization were successfully undertaken in 17
(94.4%) of 18 patients. In the remaining patient, superselective catheterization proved impossible. This patient was
treated with an injection of microparticles completed by means of embolization of biologic glue more proximally in an
iliolumbar branch. During follow-up (mean, 13.3 months) after embolization, the aneurysm sac shrank in 13 (72.2%)
of 18 patients. A new type II endoleak was diagnosed on helical computed tomography or magnetic resonance imag-
ing in two (11.1%) of 18 patients.
Conclusion: Percutaneous embolization is a safe and effective technique for treatment of type II endoleaks. However,
despite these initially promising results, large long-term follow-up studies will be required to confirm its efficiency.
(J Vasc Surg 2001;34:600-5.)
injected through the pigtail, without clinical significant
modification of the blood pressure (all patients were mon-
itored by means of a cardioscope and a device for indirect
noninvasive automatic mean arterial pressure). An initial
aortogram in the frontal plane was performed with the
catheter positioned at the level of the renal arteries.
Subsequently, the pigtail catheter was positioned in the
body of the stent, and injections were performed in
frontal, right anterior oblique, and left anterior oblique
planes. Finally, a selective injection, through a 4F pre-
shaped catheter, was performed in the superior mesenteric
artery (SMA) and in the hypogastric artery ipsilateral to
the puncture site. Each aortic injection was performed
with 30 mL of contrast medium (sodium meglumine
ioxaglate, 320 mg of iodine per milliliter) injected at a rate
of 20 mL/s. The total volume of contrast injected was
approximately 150 mL. All examinations were obtained
with a computer-assisted digital subtraction technique.
Arteriography usually allowed an assessment of the
type of endoleak. Type I endoleaks were identified as con-
trast medium uptake in the aneurysm sac rapidly after
injection, with the catheter positioned in the aorta or in
the body of the stent. For type II endoleaks, it was neces-
sary in nine (50%) of 18 patients to perform a comple-
mentary selective injection of the SMA or of a hypogastric
artery after the aortic injection to visualize the origin of
the endoleak.
A type II endoleak almost always involved at least two
arteries, one responsible for the inflow into the aneurysm
sac, and the other responsible for the outflow.
Embolization procedures. Embolization was per-
formed immediately after the diagnostic angiogram for the
first four patients and 2 to 3 weeks after the diagnostic
angiogram for the other 14 patients. We switched our pro-
tocol from immediate to delayed treatment of type II
endoleaks to avoid excessive injection of contrast media.
The initial arterial access site, in all cases except one, was
via an ipsilateral femoral approach for iliolumbar endoleaks
and via a right femoral approach for IMA endoleaks. In
one patient, in whom the aneurysmal sac was perfused by
means of an iliolumbar feeder artery, a brachial approach
was preferred. In all cases, a 5F introducer was used. The
SMA or the hypogastric artery, as appropriate, was selec-
tively catheterized with a 5F Cobra or Sidewinder catheter
(Cordis Johnson & Johnson, Boulogne Billancourt,
France) over a hydrophilic 0.035-in guidewire (Terumo,
St Quentin en Yvelines, France). Heparin was never given
during the embolization procedures.
When the feeding vessel arose from the SMA (n = 6),
a 4F Glide catheter (Terumo) was positioned in the mid-
dle colic artery. Then, a vasodilator (molsidomine, 1 mg)
was systematically injected through the catheter.
Subsequently, a rapid transit 3F microcatheter (Cordis),
135 cm in length, was advanced over a 0.018-in guidewire
through the mesenteric arch of the mesocolon and posi-
tioned at the ostium of the IMA. This maneuver was
attempted and achieved in all cases (n = 6). Contrast injec-
tion was performed as a means of confirming the presence
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of filling of the sac of the aneurysm. The direction of flow
was not clearly specified because the injection through the
IMA could cause reversal of flow.
When the feeding vessel arose from an iliolumbar
artery (n = 12), the 5F catheter (Cobra or Sidewinder) was
positioned at the origin of the vessel. Then a digital sub-
traction angiogram was performed as a means of deter-
mining with precision which branch was feeding the
aneurysmal sac. Subsequently, this branch was selectively
catheterized with the 3F microcatheter, after intra-arterial
Fig 1. Axial transverse view at level of aortic aneurysm treated by
means of bifurcated stent-graft implantation. There is a heteroge-
neous signal (A) within thrombus on T1-weighted image, with
Gadolinium uptake on post-Gadolinium scan at same level (B).
injection of a vasodilator, with a road mapping technique.
The artery was carefully catheterized as far as the origin of
the lumbar artery, and the microcatheter was placed at the
junction of the right and left lumbar arteries into the
aorta. This maneuver was attempted in all cases (n = 12),
and achieved in 11 (91.7%) of 12 cases.
Embolization was performed with a mixture of bio-
logic glue and Lipiodol (Guerbet, Roissy, France) or
Microcoils (Cook, Charenton, France). The biologic glue
solution used comprised 0.5 mL of Histoacryl (Braun
Celsa, Boulogne Billancourt, France) mixed with 0.5 mL
of Lipiodol when embolization concerned a lumbar artery
and 0.2 mL of Lipiodol when embolization concerned the
IMA. Lipiodol allowed visualization of the Histoacryl
injection and prevented the solution from becoming solid
too quickly. Its volume was reduced for IMA embolization
to avoid any migration of the mixture in the IMA collat-
erals. The mixture was deliberately more fluid for lumbar
artery embolizations to facilitate its migration from its
delivery site, at the ostium of the vessel responsible for the
inflow into the aneurysm sac, to the ostium of the vessel
concerned by the outflow. The catheter was flushed with
0.5 mL of 5% glucose solution, and the microcatheter was
removed immediately to prevent its adhesion to the
embolized glue.
A control angiogram was systematically performed at
the end of the procedure as a means of assessing the final
result. Subsequently, patients were followed up with regu-
lar helical CT scans, MRI, or both, at 3, 6, and 12 months
after the embolization procedure.
RESULTS
During follow-up after stent-graft implantation, 18
type II endoleaks were confirmed by means of angiogra-
phy. Type II endoleak occurred in 18 (30%) of 60 patients
with a mean (± SD) age of 69 ± 11 years. Sixteen of these
patients had Vangard stentgrafts; two patients had Talent
stentgrafts. The type II endoleak was a primary endoleak
(detected during the perioperative period) in 10 (55.6%)
of 18 patients and a secondary endoleak (or late endoleak)
in 8 (44.4%) of 18 patients. Secondary endoleaks were
diagnosed at 3 months (n = 1), 6 months (n = 3), 12
months (n = 3), and 18 months (n = 1) after stent-graft
implantation.
During follow-up after stent-graft implantation, two
type I endoleaks were also confirmed by means of angiog-
raphy. Seven endoleaks that were not confirmed by means
of angiography were detected by means of MRI or helical
CT. If we consider angiography to be the gold standard
for endoleak detection, these seven endoleaks can be con-
sidered to be false-positive results by means of MRI or
helical CT for endoleak detection; however, if we consider
MRI, helical CT, or both to be more sensitive than
angiography for endoleak detection, these seven endoleaks
can also be considered to be false-negative results with
angiography.
In type II endoleaks, inflow into the aneurysm sac
from the IMA with outflow through patent iliolumbar
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arteries was diagnosed in six (33.3%) of 18 patients. Inflow
from an iliolumbar artery with outflow through another
iliolumbar artery was diagnosed in 12 (66.7%) of 18
patients. In three (25%) of 12 patients, the inflow origi-
nated from two separated iliolumbar arteries. The 18 type
II endoleaks were treated by means of embolization.
In 16 patients, the procedure was undertaken via the
femoral approach. In two patients, the procedure was
undertaken through the brachial artery, in one case elec-
tively and in the second case after failure to catheterize an
iliolumbar branch via the femoral approach.
In 16 (88.9%) of 18 patients biologic glue was used for
the procedure. Representative arteriograms before and after
embolization of a type II endoleak caused by reentry ilio-
lumbar arteries are shown in Figs 2 and 3. Catheterization
of the ostia of the iliolumbar arteries in the aneurysm sac was
a success in all patients except one. This patient had
microparticles (Ivalon, Nycomed, Paris, France) injection in
distal arteriolar branches in addition to embolization with
biologic glue more proximally in an iliolumbar branch.
For IMA embolizations, only one injection of glue was
necessary, and for iliolumbar embolizations, it was neces-
sary in three (25%) of 12 cases to catheterize a second
feeding branch and to repeat the embolization procedure
with a new microcatheter.
The remaining two patients were treated with
Microcoils. In one patient, the feeding artery was the
IMA, and in the second patient, the feeding artery was an
iliolumbar branch. These two patients were treated at the
beginning of our experience in endoleak embolization. In
both patients, coils were positioned at the ostium of the
artery, all the way to the hypogastric artery for the second
patient. We did not consider embolizing the hypogastric
artery itself, to avoid colic or pelvic ischemic complications
and to maintain a pathway to distal iliolumbar branches in
case of unsuccessful embolization.
In summary, 2 patients were treated with coil
embolization, 15 patients were treated with biologic glue
alone, and 1 patient was treated with biologic glue associ-
ated with microparticles injection. Overall, superselective
catheterization and embolization of the feeding branch
from the aorta were successfully undertaken in 17 (94.4%)
of 18 patients. In the remaining patient (aforementioned),
superselective catheterization proved impossible because of
a diffuse narrowing of the distal arteriolar branches.
The mean duration of the procedures was 40 minutes
for the diagnostic procedures and 80 minutes (SD, 29.3
minutes; range, 60-90 minutes) for the therapeutic proce-
dures. The mean contrast media (sodium meglumine
ioxaglate, 320 mg of iodine per milliliter) volume for
embolization procedures was 141 mL (SD, 46 mL; range,
60-200 mL). In two (11.1%) of 18 patients, postproce-
dure renal dysfunction (serum creatinine level > 150
µmol/L) was noticed. The serum creatinine level normal-
ized in both cases at 24 hours.
Complications. No major complication was
observed. Asymptomatic thrombosis of the mesenteric
arch of the mesocolon developed in one patient, but this
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had no clinical consequences. Lower back pain devel-
oped during the procedure in three patients; it resolved
with simple analgesia. None of the three patients had
any neurologic signs. No access site complication was
observed.
Follow-up after embolization. The mean follow-up
period after endoleak embolization was 13.3 months (SD,
7.2 months; range, 3-24 months). A type II endoleak was
suspected by means of postprocedure helical CT scans and
MRI in two (11.1%) of 18 patients, 6 and 12 months after
initial embolization. No complementary angiography was
performed in either patient, because the aneurysm sac had
retracted since embolization.
Overall, after embolization, the aneurysm sac shrank
in 13 (72.2%) of 18 patients. It remained unchanged in
five (27.8%) of 18 patients.
DISCUSSION
Continuing patency of arterial feeders that retro-
gradely perfuse the aneurysm after stent-graft implanta-
Fig 2. Arteriogram before (A) and after (B) embolization with
Histoacryl of an iliolumbar reentry in patient with aortic tube
stent-graft. Perfusion of the sac of the aneurysm through right and
left iliolumbar vessels at L3 level disappears after embolization.
Fig 3. Arteriogram before (A) and after (B) embolization of type
II leak caused by reentry through right iliolumbar artery. Sac of
the aneurysm is perfused via the right iliolumbar vessels at level of
L3 and L4 and by median sacral artery. After embolization, at two
sites, the sac is no longer perfused.
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tion is responsible for a persistent rupture risk.10 This
mechanism was reportedly responsible for rupture of an
AAA treated by means of surgical ligation and extra-
anatomic bypass grafting.11 Regular follow-up assessment
is necessary as a means of detecting and treating potential
leaks.12 The most frequent endoleaks seem to be type II
endoleaks. We reported a high rate of type II endoleaks in
our study (30%), probably because we performed MRI
during follow-up, and it is considered to be a sensitive
examination for locating type II endoleaks.13 Type II
endoleaks may be isolated, involving only one feeding
branch; however, multiple feeders are common. The most
common anatomic locations are the lumbar arteries and
the IMA. To our knowledge, there is no universally
accepted approach to the management of such type II
endoleaks.14 Some authors advocate percutaneous trans-
catheter embolization with coils of the feeding vessels,15
and others propose embolization of the sac itself.16
The techniques used to perform catheterization and
embolization in small vessels, such as those described in this
report, largely derive from the experience of neuroradiolo-
gists. However, the arterial feeding branches embolized in
the patients we described are generally smaller and more tor-
tuous7,17-19 than those encountered by neuroradiologists.
In our experience, the femoral access route is the most
satisfactory one for most of these procedures. We used
brachial access in only two of the 18 patients in the cur-
rent series, in one patient because we were unable to
obtain a stable position in a SMA via the femoral approach
and in the second because the take off of the iliolumbar
vessel that was the target vessel for the intervention made
access from the femoral approach impossible.
When selective catheterization of an iliolumbar vessel
was undertaken, the 5F catheter was only advanced to the
ostium of the vessel because of the small caliber of such
vessels and their propensity for vasospasm; subsequent
superselective catheterization with a microcatheter after
injection of intra-arterial vasodilators allowed us to reach
the site of embolization in all cases except one. However,
on several occasions, multiple injections of vasodilators
were required because of the occurrence of spasm. The
use of the road mapping technique was extremely helpful
in limiting the duration of the procedures. It was difficult
to selectively catheterize the feeding vessel in one patient,
because of the large number of branch vessels at this level
and their tortuous nature.
Attempts to catheterize the mesenteric arch of the
mesocolon with the 5F catheter were quickly abandoned
because of the extremely spastic nature of the vessel and,
thus, the potential risk of thrombosis, despite the liberal
use of vasodilators. Early in our experience, thrombosis of
the mesenteric arch of the mesocolon did develop in one
patient, with no clinical consequence. Subsequently, we
only advanced the 5F catheter as far as the ostium of the
SMA, using the microcatheter to negotiate the mesenteric
arch of the mesocolon to the level of the ostium of the
inferior mesenteric artery. Since that time, no further
complication at this level was observed. We did not use
heparin during the 18 embolization procedures we
reported. This is probably another explanation for the
thrombosis diagnosed, and, given the minimal risk of
heparin in this type of procedure, its use should be rec-
ommended routinely.
The use of the microcatheter in conjunction with the
liberal administration of vasodilators is, in our view, a
major contributor to the success of the procedure. The use
of vasodilators is particularly important. The subsequent
vasodilatation allows excellent visualization of the feeding
vessels and of the extent of reentry on digital subtraction
angiograms performed through the 3F catheter.
In most patients (88.9%), we used biologic glue for the
embolization procedures. The advantage of this material
relates to the ability of a single injection to close the artery
responsible for the inflow into the aneurysm sac. The mix-
ture used for iliolumbar arteries allowed filling of the
aneurysm sac and a slight diffusion to the ostia of outflow
vessels. When a persistent endoleak was diagnosed after
glue injection (n = 3), contrast media injection revealed
another patent iliolumbar ostium, distant from the first
one, which required complementary catheterization and
glue injection.
In our experience, for patients treated by means of
biologic glue with successful catheterization (n = 15), a
single injection was sufficient to exclude the endoleak
totally in 12 (80%) of 15 patients. In those patients, the
procedure was simple, fast, and cheap. The cost of a coil
is three times higher than the cost of an injection of bio-
logic glue, and coil embolization often requires many
coils. Although the technique appears relatively simple, it
requires experienced operators. It is critical to deliver the
biologic glue at exactly the right site and to use a mixture
of glue and diluent that has the correct physical charac-
teristics, so as to avoid any embolization of the lum-
bosacral plexus or the spine. If this study confirms the
innocuity of the technique and its early positive results, it
could be considered as an alternative to coil embolization
when inflow and outflow vessels ostia close to each other
are diagnosed by means of selective angiography.
The timing of intravascular intervention to treat type
II endoleaks is an important clinical problem. There is cur-
rently no consensus on the optimal timing of intervention.
Some authors advocate measurement of the arterial pres-
sure in the aneurysmal sac to guide decision making.18,20
We did not perform such measurements, and we chose to
perform such interventions only after confirmation of a
type II leak that persisted more than 6 months. This
approach is based on primary endoleaks, with a reported
rate as high as 44% in the literature,21 sealing sponta-
neously in about half the cases. We adopted the same atti-
tude for secondary endoleaks. Other authors suggest a
more aggressive approach.
CONCLUSION
Type II endoleaks are a relatively frequent complica-
tion after stent-graft implantation for infrarenal aortic
aneurysms. Treatment by means of embolization is effec-
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tive, at least in the short term, although long-term follow-
up studies are lacking. This series shows that the use of
microcatheters in conjunction with liberal doses of intra-
arterial vasodilators led to a high rate of success, both in
catheterizing the artery responsible for the reentry and in
embolizing it. Despite the high rate of initial procedural
success, longer term follow-up is required to confirm the
efficacy of the procedure.
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